Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

Endocrine-Related Cancer

Volumn 22, Issue 1, 2015, Pages 1-9

  Cives, M ^a   Kunz, P L ^b   Morse, B ^a   Coppola, D ^a   Schell, M J ^a   Campos, T ^a   Nguyen, P T ^a   Nandoskar, P ^b   Khandelwal, V ^b   Strosberg, J R ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoid; Neuroendocrine tumors; Pasireotide; Somatostatin analogs; Somatostatin receptors

Indexed keywords

ALKALINE PHOSPHATASE; CHROMOGRANIN A; PASIREOTIDE; SOMATOSTATIN RECEPTOR 5; DELAYED RELEASE FORMULATION; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOATING; CANCER GRADING; CANCER STAGING; CHOLECYSTITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; LIVER METASTASIS; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; METABOLISM; METASTASIS; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PATHOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84923534962     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0360     Document Type: Article

References (24)

1. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L et al. 2014 Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine 371 224-233. (doi:10.1056/NEJMoa1316158)
2. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM et al. 2012 A 12-month phase 3 study of pasireotide in Cushing's disease. New England Journal of Medicine 366 914-924. (doi:10.1056/NEJMoa1105743)
3. Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K et al. 2014 Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. Journal of Clinical Endocrinology and Metabolism 99 791-799.
4. Dietrich H, Hu K, Ruffin M, Song D, Bouillaud E, Wang Y & Hasskarl J 2012 Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study. European Journal of Endocrinology 166 821-828. (doi:10.1530/EJE-11-0773)
5. Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B & International Lanreotide and Interferon Alfa Study Group 2003 Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropan-creatic tumors - the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 21 2689-2696. (doi:10.1200/JCO.2003.12.142)
6. Fazio N, Scarpa A & Falconi M 2014 Molecular targeted therapy in enteropancreatic neuroendocrine tumors: from biology to clinical practice. Current Medicinal Chemistry 21 1017-1025. (doi:10.2174/09298673113209990237)
7. van Hoek M, Hofland LJ, de Rijke YB, van Nederveen FH, de Krijger RR, van Koetseveld PM, Lamberts SW, van der Lely AJ, de Herder WW & Feelders RA 2009 Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism 94 428-433. (doi:10.1210/jc.2008-1712)
8. Kulke MH, Benson AB III, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L et al. 2012 Neuroendocrine tumors. Journal of the National Comprehensive Cancer Network 10 724-764.
9. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J & Hahn RG 1986 Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. New England Journal of Medicine 315 663-666. (doi:10.1056/NEJM198609113151102)
10. Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L et al. 2012 Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocrine-Related Cancer 19 657-666. (doi:10.1530/ERC-11-0367)
11. Nasir A, Stridsberg M, Strosberg J, Su PH, Livingston S, Malik HA, Kelley ST, Centeno BA, Coppola D, Malafa ME et al. 2006 Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control 13 52-60.
12. Ono K, Suzuki T, Miki Y, Taniyama Y, Nakamura Y, Noda Y, Watanabe M & Sasano H 2007 Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Research 27 2231-2239.
13. Rindi G & Arnold R 2010 Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In World Health Organization Classification of Tumours of the Digestive System, pp 13-14. eds F Bosman, F Carneiro, R Hruban & N Theise. Lyon, France: IARC Press.
14. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/JCO.2009.22.8510)
15. Schmid HA 2008 Pasireotide (SOM230): development, mechanism of action and potential applications. Molecular and Cellular Endocrinology 286 69-74. (doi:10.1016/j.mce.2007.09.006)
16. Schmid HA & Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80 (suppl 1) S47-S50. (doi:10.1159/000080741)
17. Shenouda M, Maldonado M, Wang Y, Bouillaud E, Hudson M, Nesheiwat D & Hu K 2014 An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels. American Journal of Therapeutics 21 164-173. (doi:10.1097/MJT.0b013e31824c3eb4)
18. Sidéris L, Dubé P & Rinke A 2012 Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist 17 747-755. (doi:10.1634/theoncologist.2011-0458)
19. Somnay Y, Chen H & Kunnimalaiyaan M 2013 Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro. Neuroendocrinology 97 183-192. (doi:10.1159/000341810)
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92 205-216. (doi:10.1093/jnci/92.3.205)
21. Villaume K, Blanc M, Gouysse G, Walter T, Couderc C, Nejjari M, Vercherat C, Cordier-Bussat M, Roche C & Scoazec JY 2010 VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 91 268-278. (doi:10.1159/000289569)
22. Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse M, Tomassetti P, Weber M, Fogelman DR, Ramage J et al. 2013a A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs. Journal of Clinical Oncology 31 (suppl; abstr 4031) 15s.
23. Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V & Resendiz KH 2013b Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemotherapy and Pharmacology 72 387-395. (doi:10.1007/s00280-013-2202-1)
24. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)